CIK 0001501989 · Accelerated filer
CytomX Therapeutics, Inc.
Sign in to watch- Ticker
- CTMX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 273521219
- Phone
- 650.515.3185
- Business address
- 151 OYSTER POINT BLVD., SUITE 400, SOUTH SAN FRANCISCO, CA, 94080
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 61 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-08-03 | Carvajal Alejandra Chief Legal Officer | Grant or award | +100,000 | 100,000 | ||
| 2026-08-03 | Carvajal Alejandra Chief Legal Officer | Grant or award · Stock Option (Right to Buy) | +450,000 | 450,000 | ||
| 2026-07-24 | Fuchs Charles S. Director | Grant or award · Stock Option (Right to Buy) | +118,000 | 118,000 | ||
| 2026-06-17 | Su Zhen Director | Grant or award · Stock Option (Right to Buy) | +59,000 | 59,000 | ||
| 2026-06-17 | Young Matthew P. Director | Grant or award · Stock Option (Right to Buy) | +59,000 | 59,000 | ||
| 2026-06-17 | Mohindru Mani Director | Grant or award · Stock Option (Right to Buy) | +59,000 | 59,000 | ||
| 2026-06-17 | Meyers James R Director | Grant or award · Stock Option (Right to Buy) | +59,000 | 59,000 | ||
| 2026-06-17 | Gilbert Halley E Director | Grant or award · Stock Option (Right to Buy) | +59,000 | 59,000 | ||
| 2026-06-17 | Ashworth Alan Director | Grant or award · Stock Option (Right to Buy) | +59,000 | 59,000 | ||
| 2026-06-17 | Jones Elaine V Director | Grant or award · Stock Option (Right to Buy) | +59,000 | 59,000 | ||
| 2026-06-15 | Ogden Christopher Chief Financial Officer | Sale | −1,624 | $3.05 | $5K | 295,324 |
| 2026-03-17 | Chu Yu-Waye Chief Medical Officer | Sale | −21,279 | $6.42 | $137K | 189,446 |
| 2026-03-17 | McCarthy Sean A. CEO | Sale 10b5-1 | −118,969 | $6.42 | $764K | 1,078,922 |
| 2026-03-17 | BELVIN MARCIA SVP, Chief Scientific Officer | Sale | −31,492 | $6.42 | $202K | 300,760 |
| 2026-03-17 | Ogden Christopher Chief Financial Officer | Sale | −19,323 | $6.42 | $124K | 296,948 |
| 2026-02-02 | Lester Rachael Chief Business Officer | Grant or award | +20,000 | 20,000 | ||
| 2026-02-02 | Lester Rachael Chief Business Officer | Grant or award · Stock Option (Right to Buy) | +50,000 | 50,000 | ||
| 2026-02-02 | Lester Rachael Chief Business Officer | Grant or award · Performance Stock Units (PSUs) | +50,000 | 50,000 | ||
| 2026-02-02 | Chu Yu-Waye Chief Medical Officer | Grant or award | +75,000 | 210,725 | ||
| 2026-02-02 | Chu Yu-Waye Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +300,000 | 300,000 |
Page 1 of 27 · 529 trades